Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey

PURPOSE: Turoctocog alfa pegol (N8-GP) is an extended half-life recombinant factor VIII molecule used for the treatment of hemophilia A (HA). The purpose of this study was to investigate real-world experiences of patients with HA treated with N8-GP. PATIENTS AND METHODS: A 25-minute online survey wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichler, Hermann, Nagao, Azusa, Waller, John, Stuber, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661914/
https://www.ncbi.nlm.nih.gov/pubmed/38027080
http://dx.doi.org/10.2147/PPA.S394216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661914/
https://www.ncbi.nlm.nih.gov/pubmed/38027080
http://dx.doi.org/10.2147/PPA.S394216

Ejemplares similares